Syndax Pharmaceuticals INC Schedule 13G passive stakes

State Street Corporation has updated its beneficial ownership filing for Syndax Pharmaceuticals Inc., reporting a 6.4% stake as of June 30, 2026.

Vanguard Capital Management has reported beneficial ownership of 5.05% of Syndax Pharmaceuticals Inc.'s common stock as of March 31, 2026.

The Vanguard Group reported a 0% beneficial ownership in Syndax Pharmaceuticals Inc. common stock due to an internal corporate realignment.

State Street Corporation has reported a 5.3% beneficial ownership stake in Syndax Pharmaceuticals Inc., holding 4,596,552 common shares.

The Vanguard Group filed an amended Schedule 13G, disclosing a 7.16% beneficial ownership in Syndax Pharmaceuticals Inc. common stock as of December 31, 2025.

Point72 Asset Management, along with Point72 Capital Advisors and Steven A. Cohen, has disclosed a 5.0% beneficial ownership stake in Syndax Pharmaceuticals Inc.

Point72 Asset Management, along with affiliates, has disclosed a 2.7% passive ownership stake in Syndax Pharmaceuticals Inc., holding 2,307,824 shares of common stock.

Goldman Sachs Group and its affiliate have reported a 6.5% beneficial ownership stake in Syndax Pharmaceuticals, Inc., holding over 5.5 million common shares.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have filed an amendment to their Schedule 13G, reaffirming a beneficial ownership of 5.2% in Syndax Pharmaceuticals, Inc.'s common stock as of March 31, 2025.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have filed an amended Schedule 13G indicating they are no longer beneficial owners of more than five percent of Syndax Pharmaceuticals Inc.'s common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.8% beneficial ownership stake in Syndax Pharmaceuticals Inc. as of March 31, 2025.

Wellington Management Group LLP and its affiliates have filed an amended Schedule 13G, reporting a beneficial ownership of 0.04% in Syndax Pharmaceuticals, Inc.'s common stock.

Kynam Capital Management, LP, along with its general partner Kynam Capital Management GP, LLC, and Yue Tang, has reported a passive beneficial ownership of 9.98% in Syndax Pharmaceuticals Inc., totaling 8,520,000 shares.

The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC have disclosed a passive beneficial ownership of 7.0% in Syndax Pharmaceuticals, Inc. common stock as of December 31, 2024.

Morgan Stanley and its subsidiary, Morgan Stanley & Co. LLC, have disclosed beneficial ownership of 6.3% of Syndax Pharmaceuticals Inc.'s common stock as of December 31, 2024.

Point72 Asset Management, L.P., along with Point72 Capital Advisors, Inc. and Steven A. Cohen, has disclosed a passive beneficial ownership of 5.0% in Syndax Pharmaceuticals Inc., totaling 4,277,847 shares.